Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
25 authors.
Dhanushika RatnayakeOncode Institute, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Center Utrecht, Utrecht, the Netherlands.ORCID 0000-0003-2476-127X
Marie Galloux *Université Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France.ORCID 0000-0001-7477-8489
Sanne Boersma *Oncode Institute, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Center Utrecht, Utrecht, the Netherlands.ORCID 0000-0003-3657-0817
Marko Noerenberg *MRC-University of Glasgow Centre for Virus Research, Glasgow, UK.ORCID 0000-0002-4834-8888
Christina SizunInstitut de Chimie des Substances Naturelles, CNRS, Université Paris-Saclay, Gif-sur-Yvette, France.ORCID 0000-0002-5760-2614
Carlos SacristanOncode Institute, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Center Utrecht, Utrecht, the Netherlands.ORCID 0000-0003-1312-2341
Anke J LakerveldCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands.ORCID 0000-0002-4386-3995
Anne T GelderloosCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands.ORCID 0000-0002-7507-7622
Leonie ApperlooOncode Institute, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Center Utrecht, Utrecht, the Netherlands.
Matthijs J D BaarsOncode Institute, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Center Utrecht, Utrecht, the Netherlands.ORCID 0000-0003-4741-051X
Rupa BanerjeeOncode Institute, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Center Utrecht, Utrecht, the Netherlands.ORCID 0000-0002-0860-8673
Birgit DreierDepartment of Biochemistry, University of Zurich, Zurich, Switzerland.
Sven FurlerDepartment of Biochemistry, University of Zurich, Zurich, Switzerland.
Natalie I MazurCenter for Translational Immunology, University Medical Centre Utrecht, Utrecht, the Netherlands.
Louis J BontCenter for Translational Immunology, University Medical Centre Utrecht, Utrecht, the Netherlands.ORCID 0000-0003-3099-4475
Shabaz MohammedDepartment of Biochemistry, University of Oxford, Oxford, UK.ORCID 0000-0003-2640-9560
Andreas PlückthunDepartment of Biochemistry, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-4191-5306
Geert J P L KopsOncode Institute, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Center Utrecht, Utrecht, the Netherlands.ORCID 0000-0003-3555-5295
Alfredo CastelloMRC-University of Glasgow Centre for Virus Research, Glasgow, UK.ORCID 0000-0002-1499-4662
Puck B van KasterenCenter for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands.ORCID 0000-0003-4369-6055
Marie-Anne Rameix-WeltiM3P unit, Institut Pasteur, Université Paris Cité, Paris, France.
Marvin E TanenbaumOncode Institute, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Center Utrecht, Utrecht, the Netherlands. m.tanenbaum@hubrecht.eu.ORCID 0000-0001-8762-0090
Funding
AbbVie, AstraZeneca, The Bill & Melinda Gates Foundation, the Dutch Lung Foundation, The Gates Medical Research Institute, GSK, Janssen, MedImmune, MeMed, Merck, Novavax, Pfizer and Sanofi
6 · The paper itself
Abstract
During infection, many RNA viruses, including respiratory syncytial virus (RSV), form specialized biomolecular condensates, viral factories (VFs), where viral transcription and replication occur
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Pre-assembly of biomolecular condensate seeds drives RSV replication. · full record | OpenQuestion